➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Colorcon
Johnson and Johnson
Merck

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIVASTIGMINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for RIVASTIGMINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00099216 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed Novartis Pharmaceuticals Phase 3 2001-08-01 The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
NCT00099242 Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease Completed Novartis Phase 3 2003-11-01 The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
NCT00102284 Neuromodulation and Language Acquisition (Project Stage Ia) Terminated University Hospital Muenster Phase 4 2004-03-01 The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RIVASTIGMINE

Condition Name

Condition Name for RIVASTIGMINE
Intervention Trials
Alzheimer's Disease 28
Alzheimer Disease 10
Delirium 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for RIVASTIGMINE
Intervention Trials
Alzheimer Disease 45
Dementia 18
Cognition Disorders 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for RIVASTIGMINE

Trials by Country

Trials by Country for RIVASTIGMINE
Location Trials
United States 149
Japan 44
Netherlands 17
Canada 17
Italy 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for RIVASTIGMINE
Location Trials
Texas 11
California 10
New York 9
Florida 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for RIVASTIGMINE

Clinical Trial Phase

Clinical Trial Phase for RIVASTIGMINE
Clinical Trial Phase Trials
Phase 4 33
Phase 3 26
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for RIVASTIGMINE
Clinical Trial Phase Trials
Completed 58
Recruiting 8
Terminated 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for RIVASTIGMINE

Sponsor Name

Sponsor Name for RIVASTIGMINE
Sponsor Trials
Novartis 19
Novartis Pharmaceuticals 14
National Institute on Drug Abuse (NIDA) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for RIVASTIGMINE
Sponsor Trials
Other 94
Industry 53
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Merck
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.